A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

计划入组 180 人 · 首次发布于 2024 年 11 月 22 日

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

计划入组 78 人 · 首次发布于 2022 年 3 月 23 日

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

计划入组 353 人 · 首次发布于 2021 年 8 月 10 日

ARO-INHBE

INHBE

ARO-PNPLA3

Arrowhead Pharmaceuticals

United States

ACO

ARS PHARMACEUTICALS

India

Arrowhead Pharmaceuticals Advances RNAi Therapies ARO-INHBE and ARO-ALK7 for Obesity Treatment

Arrowhead Initiates Phase I/IIa Trial of RNAi Therapy ARO-INHBE for Obesity

Arrowhead's Gene-Silencing Drugs Show Promise in Early Obesity Studies, Enhancing Weight Loss When Combined with Zepbound